{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-022794","form_type":"8-K","ticker":null,"cik":"0001165320","company_name":"GB SCIENCES INC","filed_at":"2024-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.316381+00:00","generated_at":"2026-05-31T20:23:39.449084+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GB Sciences appoints Dr. Small-Howard as CEO, CFO, Chairman after John Poss's death","bullets":["John Poss passed away on July 10, 2024; he led GB Sciences as CEO and Chairman since 2015.","Dr. Andrea Small-Howard promoted to CEO, CFO, and Chairman under a pre-established succession plan.","Dr. Small-Howard previously served as President for three years, overseeing day-to-day operations.","She is a founding board member and the architect of the company's cannabinoid medicine strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-022794","json":"https://secwatch.observer/filing/0001437749-24-022794.json","markdown":"https://secwatch.observer/filing/0001437749-24-022794.md","text":"https://secwatch.observer/filing/0001437749-24-022794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1165320/000143774924022794/0001437749-24-022794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1165320/000143774924022794/gblx20240716_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:23:39.449084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c87d0ded3","claim":"Dr. Andrea Small-Howard was appointed as Chief Executive Officer, Chief Financial Officer, and Chairman at GB SCIENCES INC.","evidence_excerpt":"She was promoted to CEO, CFO and Chairman of the Board as a part of their succession plan, which was created due to the failing health of Mr. John Poss.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1165320/000143774924022794/0001437749-24-022794-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Executive Officer, Chief Financial Officer, and Chairman"}],"fact_type":"executive_change"},{"claim_id":"b6196ab560","claim":"John Poss departed as Chief Executive Officer and Chairman at GB SCIENCES INC.","evidence_excerpt":"Mr. Poss had battled through serious health issues and had served the company very well since 2015. Fortunately, Mr. Poss had spent years preparing Dr. Small-Howard for her expanded role as CEO, CFO and Chairman, which roles fell to her upon the passing of Mr. Poss on July 10, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1165320/000143774924022794/0001437749-24-022794-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"passed away"},{"label":"Role","value":"Chief Executive Officer and Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}